This week China imposed tariffs on imports of various U.S. agricultural products in retaliation for Trump Administration tariffs on Chinese imports. Today the Administration announced that it would consider an additional $100 billion in tariffs on Chinese goods in response.
The impact of the Chinese tariffs on U.S. exports of pork meat, cherries, almonds, and ginseng, among other items, was detailed in a new brief from the Congressional Research Service. See China’s Retaliatory Tariffs on Selected U.S. Agricultural Products, CRS Insight, April 4, 2018.
Other new and updated reports from the Congressional Research Service this week include the following.
U.S. Trade Deficit and the Impact of Changing Oil Prices, updated April 4, 2018
Immigration Consequences of Criminal Activity, April 5, 2018
Federal Research and Development (R&D) Funding: FY2019, April 4, 2018
Title I of the Toxic Substances Control Act (TSCA): A Summary of the Statute, April 4, 2018
Data, Social Media, and Users: Can We All Get Along?, CRS Insight, April 4, 2018
Abortion and Family Planning-Related Provisions in U.S. Foreign Assistance Law and Policy, updated April 5, 2018
Nuclear Cooperation with Other Countries: A Primer, updated April 3, 2018
What Happens When Five Supreme Court Justices Can’t Agree?, CRS Legal Sidebar, April 5, 2018
Confirmation that the construction of the security perimeter and associated security infrastructure at RAF Lakenheath are still ongoing once again raises questions about whether U.S. nuclear weapons have already been deployed to the base.
Alaskans are sensibly pulling back from the vogue for bans and returning to a western tradition that has worked for more than half a century – one that welcomes innovation but also oversees it closely.
The strength of our nation’s data policy isn’t just in the rules we write, but in how effectively we translate those rules into a system that prioritizes the public good. Join us in this movement to design and build more resilient national data policies.
The human cost is measured in deaths. The financial cost is measured in the $52 billion taxpayers pay annually end stage renal disease – double NASA’s budget.